Skip to main content

Vank's disease: A compelling need to decrease Anti Tubercular (TB) drug resistance



Tuberculosis is an infectious and contagious disease caused by a bacteria called Mycobacterium tuberculosis. Tuberculosis primarily affects the lungs, symptoms include: chronic cough with blood in Phlegm, fever.


Pharmacovigilance imparts a vital role in monitoring serious Adverse drug reactions (ADRs) in TB patients who are on treatment in national TB program.

ADRs could lead to a tuberculosis (TB) patient interrupting treatment before completion, and can thus contribute to avoidable morbidity, drug-resistance, treatment failure, reduced quality of life, or death.

Tuberculosis is completely curable using short term chemotherapy called DOTS or Directly Observed Treatment Short course. However, there are several challenges encountered by patient to get DOTS treatment in India. Some of the challenges include coping up with DOTS strategy. In a recent research paper published by (research, team name), it had a study which in which TB patients were interviewed, the paper says ‘Poor patients residing in rural areas faced the greatest difficulty in overcoming the barriers.

They had to travel long distances every alternative day to reach a DOTS centre, had to put up with inconvenient timings’ and “unfavorable attitude” of the staff’,
Lack of proximity to a DOTS center, inconvenient timings, and lack of patient awareness eventually leads to Multi-drug-resistant tuberculosis, specifically prominent in Patients from rural parts of country.

Multi-drug-resistant tuberculosis or Vank's disease is caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB drugs.

Treatment to DOTS is now becoming difficult with increase in drug resistance, Pharmacovigilance plays a vital role in drug monitoring for Multi-drug-resistant anti-TB drugs. Drug resistance is caused when:

·Patients do not complete a full course of TB treatment
·Health care professional prescribe the wrong treatment (the wrong dose or length of time)
·Drugs for proper treatment are not available
·Drugs are of poor quality
·Further Drug-resistance is more common in people who
·Do not take their TB drugs regularly
·Do not take all of their TB drugs
·Develop TB disease again, after being treated for TB disease in the past
·Come from areas of the world where drug-resistant TB is common
·Have spent time with someone known to have drug-resistant TB disease

Apart from drug resistance patients also experience ADR from the DOTS drug regime ADRs could include hearing loss to dizziness, rashes, anorexia, abdominal pain, nausea, and vision loss. Immediate medical attention is required on a time-bound basis to stop the drug and control the reaction after which an alternate medication is prescribed.

Recently The Pharmacovigilance Programme of India (PvPI), which has identified the SDS TB Research Centre, Rajiv Gandhi Institute of Chest Diseases (RGICD) to monitor adverse drug reactions (ADRs), is now working to have a centre for research and training. The objective is to educate its nurses and doctors on early detection of ADR caused by TB and lung infection medications.

Reference:

By,
Joseph Mathew
Senior Manager- Pharmacovigilance
Think i

Think-I - an organization providing technological solutions and result oriented quality services in Pharmacovigilance, Clinical Trials, Medical Writing, Drug Regulatory Affairs and Human Resources.

We provide cloud based software solutions for pharmacovigilance which are not only cost effective and user friendly but also fully validated for quick, easy import, entry and electronic submissions of adverse event.
Labels:

Comments

Post a Comment

Popular posts from this blog

Artificial Intelligence Seeing through the lens of Pharmacovigilance

Pharmacovigilance as we know is a science with a set of pre defined functions to collect, analyse, monitor adverse event reports in understanding the safety profile of drug. The set pre defined functions would include case processing through data entry of adverse event forms into safety database, medical review, aggregate reporting, signal detection, risk evaluation and mitigation strategies. With patients awareness and regulatory compliance we may have seen a surge of adverse event data over last few years , resulting in the urgent need for the application of automation. Pharmacovigilance is the only discipline where in which timelines and quality data are evaluated on a benchmark of 100 % and a compromise in these two parameters are considered to be a zero tolerance. Automation of above pre defined function is possible through machine learning, which is an integral components of Artificial Intelligence. What is Artificial Intelligence ?     ...
2 comments
Read more

What is a ‘backward forward convertor’ ?

Did you know that ICH has a backward forward conversion (BFC) tool which was build using eXtensible Stylesheet Language Transformation (XSLTs) ? This language basically transforms a XML file of a given format into another XML file of a different format. The BFC tool requires a program that understands XSLT language to make conversion of E2B (R2) to E2B (R3) and vice versa. Now considering this, the European medical agency has improvised the BFC tool with additional fields as per the EU implementation guide. The EU version of the amended BFC tool has been published on the EMA website. The key files in the BFC package includes downgrade-icsr.xsl; which downgrades E2B (R3) file into E2B (R2) and upgrade-icsr.xsl; which upgrades E2B (R2) file into an E2B (R3) file. The acknowledgement convertors include downgrade-ack.xsl and upgrade-ack.xsl What are the technical limitations of BFC tools? However, the conversion using BFC has some major limitations. When converting I...
Post a Comment
Read more

Eritrea ranked top by UMC- WHO in ADR reporting

Eritrea an African country located in the north east region on the red coast sea bordering Ethiopia and Sudan, has been reported as the top country in reporting adverse drug reaction through safety reports submitted to global database by the Uppsala Monitoring Centre (Sweden), the collaborating centre for WHO as part of their international drug monitoring programme. The Pharmacovigilance programme of Eritrea was carried out at maturity LEVEL THREE as per UMC with the assistance of local strength engaged in providing harmonization. Eritrea has identified 11 safety concerns on their medicinal products, which were also published in international peer reviewed journals. The Eritrean work on Pharmacovigilance has been globally acknowledged with insights on revising the policy of Eritrean Healthcare system. Recognizing the significant contribution made in pharmacovigilance,Eritrea along with Netherlands and Peru has been invited for the upcoming 40 th Anniversary of UMC o...
2 comments
Read more